Akums bags key EU GMP certifications for 2 Haridwar plants
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
The Ma’anshan site approval covers pastilles, oral liquids, and powders
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Subscribe To Our Newsletter & Stay Updated